RADIANCE 1

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.

The objective of this study is to look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia. The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Pfizer

The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00136981.

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00136981.

• Diagnosis of heterozygous familial hypercholesterolemia
• At least 18 years of age

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

• Change in intima media thickness as measures by carotid ultrasound

• Changes in levels of lipids and other biomarkers

The administration of torcetrapib with atorvastatin among patients with familial hypercholesterolemia did not lead to decrease in the progression of atherosclerosis as compared with atorvastatin alone.^[1]